Delivery Order SPE2DB22D3401-SPE2DB26FT0TQ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,229.20 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml syringes to be delivered to Conshohocken, Pennsylvania. The contract was awarded on September 3, 2025, as a firm fixed-price delivery order without a set-aside designation, with an ultimate completion date of September 24, 2025. This award represents a competitive procurement for a specialized pharmaceutical product used in the treatment of systemic lupus erythematosus....
- The Defense Logistics Agency awarded a $12,305.60 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml syringes, with an ultimate completion date of October 1, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is one of the nation's largest pharmaceutical distributors and serves as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency awarded a delivery order valued at $3,076.40 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml syringes. The contract, issued on August 11, 2025, carries a firm fixed price and is scheduled for completion by September 2, 2025. This is a competitive award with no set-aside designation, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used primarily to treat...
- The Defense Logistics Agency awarded a $6,152.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Benlysta 200 mg/ml syringes. This non-set-aside contract will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of October 1, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a...
- The Defense Logistics Agency awarded a delivery order valued at $6,152.80 to AmerisourceBergen Drug Corp on July 8, 2025, for the supply of Benlysta 200 mg/ml syringes. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 29, 2025, with performance at the contractor's Conshohocken, Pennsylvania location. The contract carries no set-aside designation, reflecting the competitive nature of the procurement. This delivery order is issued under...
- The Defense Logistics Agency awarded a $9,229.20 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml syringes, with an ultimate completion date of August 12, 2025. This non-competitive delivery order utilizes firm fixed pricing and is being performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta is a biologic medication used to treat systemic lupus erythematosus and lupus nephritis, representing a specialized pharmaceutical product within the federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Benlysta 200 mg/mL syringes valued at $6,152.80, with completion targeted for September 2, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply requirements. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99...
- The Defense Logistics Agency awarded a delivery order valued at $10,518.48 to AmerisourceBergen Drug Corp for the supply of Benlysta 400 mg vials, with an ultimate completion date of September 2, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a single procurement action under the company's broader pharmaceutical supply agreement with the federal government. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $9,248.01 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on September 19, 2025, with an ultimate completion date of October 10, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $6,152.80 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Benlysta 200 mg/ml syringes. This firm fixed-price delivery order will be completed by September 18, 2025, and represents a competitive award with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office operations. This delivery...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB26FT0TQDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $18,458.40 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml syringes. The contract, issued on November 7, 2025, with an ultimate completion date of December 2, 2025, utilizes a firm fixed-price delivery order structure with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Benlysta, a treatment used for systemic lupus erythematosus, represents one of the specialized pharmaceutical products available through this strategic contract vehicle, which supports customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.5k | 11/7/25 |